News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Akash Maniam: Talazoparib and Enzalutamide will change the approach to mCRPC
Photo from Akash Maniam/LinkedIn
Oct 20, 2024, 17:53

Akash Maniam: Talazoparib and Enzalutamide will change the approach to mCRPC

Akash Maniam, Medical Oncologist of Portsmouth Hospitals University NHS Trust, shared on LinkedIn:

“Brilliant. This will change our approach to 1L mCRPC.

OS benefits across all comers for talazoparib + enzalutamide vs enzalutamide, backing up the PFS benefits reported previously. Congratulations Neeraj Agarwal and the entire team for continuing to advance care for a challenging clinical scenario.

This also reinforces the meta-analysis we did Giuseppe Banna quite nicely on PARP inhibitor + ARSI combinations.”

Akash Maniam

Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis

Authors: Carlo Messina, Emilio Francesco Giunta, Alessio Signori, Sara Elena Rebuzzi, Giuseppe Luigi Banna, Akash Maniam, Sebastiano Buti, Carlo Cattrini, Giuseppe Fornarini, Matteo Bauckneht, Alastair Greystoke, Ruth Plummer, Christoph Oing, Pasquale Rescigno

Akash Maniam: Talazoparib and Enzalutamide will change the approach to mCRPC

More posts featuring Akash Maniam on oncodaily.com

Akash Maniam Alastair Greystoke Alessio Signori cancer Carlo Cattrini Carlo Messina Christoph Oing Emilio Francesco Giunta Giuseppe Fornarini Giuseppe Luigi Banna Matteo Bauckneht OncoDaily Oncology Pasquale Rescigno Ruth Plummer Sara Elena Rebuzzi Sebastiano Buti
Special Coverage
Science
Dec 21, 2024, 07:05
Naseema Gangat: Practical prognostic tool for the current standard of care in older/unfit AML
Blog
Dec 21, 2024, 05:54
LCC in Spanish: LALCA 2024 Highlights
Blog
Dec 21, 2024, 05:50
The Opportunities Are Endless: CU Cancer Center leader Enrique Soto Pérez de Celis signs key international agreement
Insight
Dec 21, 2024, 05:42
Raffaella Casolino: How to integrate cancer into crisis?
Insight
Dec 21, 2024, 05:01
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
Blog
Dec 21, 2024, 05:01
Omolola Salako: A year ago, Pearl Oncology Specialist Hospital became a 24-hour, 10-bed cancer center
Science
Dec 21, 2024, 04:57
Alexandre Chan: Updates on repurposing riluzole as a treatment for cancer-related cognitive impairment
Blog
Dec 21, 2024, 04:55
Milan Mishkovikj: The Patient at the Center - Value-Based Healthcare in Oncology
Insight
Dec 21, 2024, 04:52
Do national cancer control plans address care and research for children and AYAs - SIOP
Insight
Dec 21, 2024, 04:36
A holistic global strategy for incorporating cancer care into crisis response initiatives - The Institute of Cancer and Crisis
Opinion
Dec 21, 2024, 03:42
The Dorcas Cancer Foundation's 12 Days of Thankful Giving
Blog
Dec 21, 2024, 03:31
The future of cancer diagnostics with Robotic Bronchoscopy - CLIRNET